Avalo Therapeutics reports 2022 net loss of $41.7M; Phase 2 PEAK trial enrollment complete

Avalo Therapeutics, Inc.

Net loss of $41.7M for 2022, improved from $84.4M in 2021; net loss per share $4.43.
Total revenues $18.1M, up from $5.4M, driven by $14.5M upfront from AVTX-007 out-license.
Cash and equivalents $13.2M at Dec 31, 2022; raised $13.7M net in Feb 2023 public offering.
Completed enrollment of Phase 2 PEAK trial of AVTX-002 in non-eosinophilic asthma (91 patients); topline data expected Q2 2023.
Identified lead molecule for AVTX-008 (BTLA agonist); target IND submission in 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.7

Avalo Therapeutics, Inc. reported financial results for the year ended December 31, 2022.

Period: the year ended December 31, 2022
Result: reported results

Exact text from the filing

On March 29, 2023, Avalo Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the year ended December 31, 2022.

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

Avalo Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-23-009629

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.